

Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Effective: November 1, 2019

Next Review: August 2020

Last Review: September 2019

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

The use of hematopoietic cell transplantation (HCT, previously referred to in this policy as a hematopoietic stem cell transplant [HSCT]) has been investigated for treatment of patients with epithelial ovarian cancer. Hematopoietic cell transplantation is performed to restore normal function following chemotherapy treatment.

MEDICAL POLICY CRITERIA

Note: HCT to treat *germ cell* tumors of the ovary is considered in a separate medical policy (see Cross References).

Autologous and allogeneic hematopoietic cell transplantation are considered **investigational** to treat epithelial ovarian cancer.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

POLICY GUIDELINES

DEFINITIONS

- **Consolidation therapy:** Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells. Also called intensification therapy and postremission therapy.
- **Relapse:** The return of a disease or the signs and symptoms of a disease after a period of improvement.
- **Salvage therapy:** Treatment that is given after the cancer has not responded to other treatments.
- **Tandem transplant:** Refers to a planned second course of high-dose therapy and HCT within six months of the first course.

CROSS REFERENCES

1. [Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Cell Transplant](#), Transplant, Policy No. 45.03
2. [Placental and Umbilical Cord Blood as a Source of Stem Cells](#), Transplant, Policy No. 45.16
3. [Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults](#), Transplant, Policy No. 45.27
4. [Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors](#), Transplant, Policy No. 45.38

BACKGROUND

HEMATOPOIETIC CELL TRANSPLANTATION

Broadly speaking, there are two types of hematopoietic cell transplants (HCT, previously referred to in this policy as a hematopoietic stem cell transplant [HSCT]), autologous and allogeneic. The purpose of an autologous HCT is to treat a disease (e.g. lymphoma) with myeloablative doses of chemotherapy (with or without radiation) that are active against the disease. The recipient's own HCTs (collected previously) are infused after the chemotherapy in order to re-establish normal marrow function. In an allogeneic transplant, the recipient receives HCTs from a donor after myeloablative therapy or non-myeloablative therapy in order to re-establish normal marrow function as well as to use the new blood system as a platform for immunotherapy, a so called "graft versus tumor" effect. Hematopoietic cells can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the cells in it are antigenically "naïve" and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). HCT is an established treatment for certain hematologic malignancies; however, its use in solid tumors in adults continues to be largely experimental.

EPITHELIAL OVARIAN CANCER

Several different types of malignancies can arise in the ovary; epithelial carcinoma is the most common. Epithelial ovarian cancer is the fifth most common cause of cancer death in women. New cases and deaths from ovarian cancer in the United States in 2015 are estimated at 21,290 and 14,180, respectively.^[1] Most ovarian cancer patients present with widespread disease, and yearly mortality is approximately 65% of the incidence rate.

The current management of advanced epithelial ovarian cancer is cytoreductive surgery followed by combination chemotherapy.^[2] Approximately 75% of patients present with International Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian cancer, and treated with the combination of paclitaxel and a platinum analog being the preferred

regimen for newly diagnosed advanced disease.^[2,3] The use of platinum and taxanes has improved progression-free survival (PFS) and overall survival (OS) rates in advanced disease to 16–21 months and 32–57 months, respectively.^[3] However, most of these women develop recurrences and die of their disease as chemotherapy drug resistance leads to uncontrolled cancer growth.^[2]

High-dose chemotherapy (HDC) has been investigated as a way to overcome drug resistance. However, limited data exist on this treatment approach, and the ideal patient population and best regimen remain to be established.^[2] Hematopoietic cell transplantation has been studied in a variety of patient groups with ovarian cancer as follows:

- to consolidate remission after initial treatment
- to treat relapse after a durable response to platinum-based chemotherapy
- to treat tumors that relapsed after less than six months
- to treat refractory tumors

EVIDENCE SUMMARY

The principal outcomes associated with treatment of malignancies are typically measured in units of survival past treatment: disease-free survival (DFS), a period of time following treatment where the disease is undetectable; progression-free survival (PFS), the duration of time after treatment before the advancement or progression of disease; and overall survival (OS), the period of time the patient remains alive following treatment. Risk of graft-versus-host disease is another primary outcome among patients undergoing allogeneic hematopoietic transplantation (HCT). Ideally, in order to understand the impact of HCT for treatment of epithelial ovarian cancer, comparative clinical trials that compare this therapy to standard medical treatment are needed. Further, for treatment of malignancies, particularly those with a poor prognosis, an understanding of any adverse treatment effects must be carefully weighed against any benefits associated with treatment to understand the net treatment effect.

TECHNOLOGY ASSESSMENTS

Initially, this policy was based on a 1998 BlueCross BlueShield Association Technology Evaluation Center (TEC) Assessment, “High-dose chemotherapy with autologous stem cell support for epithelial ovarian cancer”^[4] that reached the following conclusions:

Data were unavailable from randomized controlled trials for any of the patient groups studied (see Description). Thus, the Assessment was able to compare outcomes only indirectly, using separate studies of high-dose chemotherapy (HDC) and conventional dose regimens.^[4] Although some results reported after high-dose therapy appeared encouraging, the indirect comparisons did not permit conclusions.

In previously untreated patients, reported response rates suggested that high-dose therapy increased the objective response rate compared to patients given conventional-dose chemotherapy. However, this comparison was flawed by age bias and by differences in performance status and other baseline characteristics of patients included in the two sets of studies. Response duration and survival data were unavailable for comparison. Treatment-related mortality was greater after high-dose therapy.

In previously treated patients, objective response rates after HDC also were reportedly higher than after conventional-dose regimens. Subgroup analyses showed higher

response rates among platinum-sensitive, optimally debulked patients. Minimum values of the ranges reported across studies for median response duration and survival after HDC were similar to those reported after conventional-dose chemotherapy. However, the maxima for these ranges suggested improved response duration and overall survival after high-dose therapy. In contrast, data from the Autologous Blood and Marrow Transplant Registry did not show similarly high survival for comparable subgroups. Comparison with conventional-dose chemotherapy was again biased due to differences in age distributions, performance status, and other baseline characteristics of patients included in studies of high-dose or conventional therapies.

The 1998 TEC Assessment did not identify any studies reporting outcomes of allogeneic transplants for patients with ovarian cancer.^[4] A separate 1999 TEC Assessment evaluated the use of HDC with allogeneic stem-cell support (HDC/AlloSCS) as salvage therapy after a failed prior course of HDC/AuSCS.^[5] There were no data regarding outcomes of this strategy as therapy for epithelial ovarian cancer.

RANDOMIZED CONTROLLED TRIALS

Mobus (2007) reported on a randomized phase III trial that included 149 patients with untreated ovarian cancer who were randomly assigned, after debulking surgery, to standard chemotherapy or sequential HDC and peripheral blood stem-cell support.^[3] This was the first randomized trial comparing HDC to standard chemotherapy as first-line treatment of ovarian cancer, and the investigators found no statistically significant difference in progression-free survival (PFS) or overall survival (OS) between the two treatment options. The study was powered such that a sample of 208 patients would be needed to detect an absolute improvement of 15% in PFS with a power of 80% and a one-sided alpha of 5%. The median patient age was 50 years (range: 20–65) and FIGO stage was IIb/IIc in 4%, III in 78%, and IV in 17%. Seventy-six percent of patients in the HDC arm received all of the scheduled chemotherapy cycles. After a median follow-up of 38 months, PFS was 20.5 months in the standard chemotherapy arm and 29.6 months in the HDC arm (hazard ratio [HR]: 0.84; 95% CI: 0.56–1.26; $p=0.40$). Median OS was 62.8 months in the standard chemotherapy arm and 54.4 months in the HDC arm (HR: 1.17; 95% CI: 0.71–1.94; $p=0.54$).

Papadimitriou (2008) reported on randomized controlled trial (RCT) the use of HDC with stem-cell support as consolidation therapy in patients with advanced epithelial ovarian cancer (FIGO stage IIC-IV).^[2] Patients who achieved first clinical complete remission after conventional chemotherapy were randomly assigned to receive or not receive high-dose melphalan and autologous cell transplant. A total of 80 patients were enrolled in the trial. Of the 37 patients allocated to HDC, 11 did not receive the treatment either due to refusal or failure of peripheral blood stem-cell mobilization. In an intent-to-treat analysis, there were no significant differences between the two arms in time-to-disease progression ($p=0.059$) or OS ($p=0.38$).

NONRANDOMIZED STUDIES

Experience with HCT in epithelial ovarian cancer comes primarily from registry data and phase II studies.^[6-11] Over the last 20 years, more than 1,000 patients have been entered on transplant registries in Europe and in the United States.^[3,6,7] Many of the registry patients were treated in relapse and others in non-randomized studies using HDC as first-line treatment.

Case selection and retrospective review make the interpretation of the registries and non-randomized data difficult.^[3] Survival analyses from registry data and clinical trials suggested a

possible benefit treating ovarian cancer patients with HCT.^[3] However, as outlined above, none of the randomized trials have provided evidence that HCT in ovarian cancer provides any outcome benefit.

SUMMARY OF EVIDENCE

For individuals who have advanced-stage epithelial ovarian cancer who receive HCT, the evidence includes randomized trials and data from case series and registries. Relevant outcomes are overall survival, disease-specific survival, change in disease status, and treatment related mortality and morbidity. Although some of the observational studies have reported longer survival in subsets of women with advanced epithelial ovarian cancer than women treated with standard chemotherapy, none of the randomized trial evidence has shown any benefit from HCT in this population. Overall, the evidence has not shown that HCT improves health outcomes in treating epithelial ovarian cancer, including survival, compared with conventional standard doses of chemotherapy. The evidence is insufficient to determine the effects of the technology on health outcomes.

PRACTICE GUIDELINE SUMMARY

No current clinical practice guidelines from professional societies address hematopoietic cell transplantation for epithelial ovarian cancer.

SUMMARY

More research is needed to know how well hematopoietic cell transplantation (HCT) works to treat people with epithelial ovarian cancer. In addition, there are no clinical practice guidelines from professional societies that recommend HCT for these patients. Therefore, the use of HCT for the treatment of epithelial ovarian cancer is considered investigational.

REFERENCES

1. Physician Data Query (PDQ). Ovarian epithelial cancer treatment (PDQ®). National Cancer Institute, U.S. National Institute of Health. [cited 09/11/2019]; Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/HealthProfessional>
2. Papadimitriou, C, Dafni, U, Anagnostopoulos, A, et al. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. *Bone Marrow Transplant*. 2008 Mar;41(6):547-54. PMID: 18026149
3. Mobus, V, Wandt, H, Frickhofen, N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. *J Clin Oncol*. 2007 Sep 20;25(27):4187-93. PMID: 17698804
4. TEC Assessment 1998. "High Dose Chemotherapy with Autologous Stem-cell Support for Epithelial Ovarian Cancer." BlueCross BlueShield Association Technology Evaluation Center, Vol. 13, Tab 6.

5. TEC Assessment 1999. "Salvage HDC/AlloSCS for Relapse following HDC/AuSCS for Non-lymphoid Solid Tumors." BlueCross BlueShield Association Technology Evaluation Center, Vol. 14, Tab 11.
6. Stiff, PJ, Veum-Stone, J, Lazarus, HM, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. *Ann Intern Med.* 2000 Oct 3;133(7):504-15. PMID: 11015163
7. Ledermann, JA, Herd, R, Maraninchi, D, et al. High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.* 2001 May;12(5):693-9. PMID: 11432630
8. Stiff, PJ, Bayer, R, Kerger, C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. *J Clin Oncol.* 1997 Apr;15(4):1309-17. PMID: 9193322
9. Donato, ML, Aleman, A, Champlin, RE, et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. *Bone Marrow Transplant.* 2004 Jun;33(12):1219-24. PMID: 15122311
10. Bay, JO, Cabrespine-Faugeras, A, Tabrizi, R, et al. Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experience. *Int J Cancer.* 2010 Sep 1;127(6):1446-52. PMID: 20049839
11. Sabatier, R, Goncalves, A, Bertucci, F, et al. Are there candidates for high-dose chemotherapy in ovarian carcinoma? *J Exp Clin Cancer Res.* 2012;31:87. PMID: 23072336
12. BlueCross BlueShield Association Medical Policy Reference Manual "High-Dose Chemotherapy and Hematopoietic Stem-Cell Support for Epithelial Ovarian Cancer." Policy No. 8.01.23

CODES

Codes	Number	Description
CPT	38204	Management of recipient hematopoietic cell donor search and cell acquisition
	38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, allogeneic
	38206	;autologous
	38207	Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage
	38208	;thawing of previously frozen harvest, without washing, per donor
	38209	;thawing of previously frozen harvest with washing, per donor
	38210	;specific cell depletion with harvest, T cell depletion
	38211	;tumor cell depletion
	38212	;red blood cell removal
	38213	;platelet depletion
	38214	;plasma (volume) depletion
	38215	;cell concentration in plasma, mononuclear, or buffy coat layer
	38220	Diagnostic bone marrow; aspiration(s)
	38221	Diagnostic bone marrow; biopsy(ies)

	38222	Diagnostic bone marrow; biopsy(ies) and aspiration(s)
	38230	Bone marrow harvesting for transplantation; allogeneic
	38232	Bone marrow harvesting for transplantation; autologous
	38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
	38241	;autologous transplantation
	38243	;HPC boost
	38242	Allogeneic lymphocyte infusions
HCPCS	S2140	Cord blood harvesting for transplantation; allogeneic
	S2142	Cord blood derived stem-cell transplantation, allogeneic
	S2150	Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)

Date of Origin: May 2010